Novo Nordisk R&D has renewed its research award program which helps new and established scientists substantiate early innovation in the area of diabetes and obesity research. Areas of research supported by the awards include (1) new biologic therapeutics and targets amenable to biologics therapeutics or novel effects of known biologics in the field of Type 1 Diabetes and Type 2 Diabetes, including microvascular complications and obesity, and (2) protein-based science technologies including oral and injection delivery concepts. Please note that only non-clinical proposals will be accepted. For more information or to apply for funding, please go to www.novonordisk-us.com/innovation.
For questions, please contact Brittany Sale.